Navigation Links
Medarex Announces 2008 Third Quarter Financial Results
Date:10/30/2008

plications for two separate antibodies generated by Medarex's UltiMAb(R) technology.

-- Announcing the receipt of a milestone payment from MedImmune, Inc. for initiation of a Phase 2a multi-dose clinical trial of MEDI-545, an anti-interferon-alpha HuMAb(TM) for systemic lupus erythematosis.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to Medarex's investments and advances related to its products in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, includin
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... June 17, 2014 Using microscopic polymer light ... gases, researchers at MIT,s Quantum Photonics Laboratory have ... in the parts-per-billion range. Optical sensors are ideal ... high signal-to-noise ratio, compact, lightweight nature, and immunity ... sensors had been developed before, the MIT team ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2
... SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ...
... 2010 Savara Inc., an inhalation product development company, ... its Board of Directors. In 1983 Mr. ... he guided the growth of that organization to over ... the largest clinical contract research organizations in the world. ...
... N.J., Nov. 8, 2010 Omthera Pharmaceuticals, ... today announced the initiation of a randomized, ... the bioavailability of Epanova™, Omthera,s lead compound ... in comparison to Lovaza®, the leading prescription ...
Cached Biology Technology:YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... historic fish, with an intriguing past, now has had ... the genetic changes that accompanied the adaptation from an ... led by Chris Amemiya, PhD, Director of Molecular Genetics ... and Professor of Biology at the University of Washington, ...
... has the ability to ward off viruses by activating a ... chain reaction that disrupts the levels of cholesterol required in ... discovered by researchers in molecular microbiology and immunology at the ... development of therapies to fight a variety of viral infections. ...
... a long time to produce in the ovary, and thus ... been theorized that the body has mechanisms to help the ... the right time in order to maximize the chance of ... Jianjun Sun has shed light on how successful ovulation and ...
Cached Biology News:Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3University of Southern California scientists reveal natural process that blocks viruses 2Reproductive tract secretions elicit ovulation 2Reproductive tract secretions elicit ovulation 3
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: